SHEEL

Sheel Biotech Limited

Listed company · ISIN INE0YJV01017 · NSE SM · FV ₹10
Last price
₹57
-3.49%today
What this company does

Sheel Biotech Limited is a listed company. It booked ₹88 cr of revenue in its latest half year (H2 FY26) and kept 13.1% of sales as profit.

70out of 100
Equitytale Health Score
Solid

Healthier than 70% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,387–2,932 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
39

At close. Not part of the score.

Profitability & returns77

How much profit it earns on the money it employs

Balance sheet78

How much it owes, and whether earnings cover the interest

Cash quality13

Whether reported profit actually arrives as cash

Valuation87

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Looks broadly healthy
Strengths
✓ Makes a profit
✓ Promoters hold 72%
✓ No promoter shares pledged
✓ Strong 22% return on equity
✓ Virtually debt-free
Watch-outs
None flagged from our data

What if I invest in SHEEL?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹57▼ -3.49%
latest close · 2026-10-29
52-wk low ₹5647 sessions so far52-wk high ₹71
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio4.2Low
LowAverageHigh
P/B ratio1.08Moderate
Below bookModerateHigh
EV / EBITDA4.3Low
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity21.7%Strong
WeakFairStrong ▸15%
Return on capital22.6%Strong
WeakFairStrong
Net margin13.1%Decent
ThinDecentStrong
EBITDA margin16.5%Decent
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.08Comfortable
LowModerateHigh ▸1
Interest cover19.0×Strong
RiskyOkayStrong ▸5×
Current ratio7.53Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹115 cr
Book value
₹52
EPS
₹6.69
latest half year
Net debt
₹9 cr
owes more than its cash
Enterprise value
₹124 cr
EBITDA
₹29 cr
annualised
EBIT
₹29 cr
annualised
Operating margin
16.5%
Return on assets
15.9%
Earnings yield
23.62%
P/S
0.65
Sales / share
₹86.6
Tax rate
16.0%
Face value
₹10
Shares
2.0 cr
Working capital
₹111 cr
Current assets
₹128 cr
Current liabilities
₹17 cr
Delivery %
95.2%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-29.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹37–₹37, midpoint ₹37

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H2 FY26 (consolidated)
Revenue from Operations₹88 cr
Other Income₹56.6 L
Total Income₹89 cr
Cost of Materials₹46 cr
Purchases of Stock-in-Trade₹0 cr
Inventory Change (±)₹12 cr
Employee Benefit Expense₹8 cr
Finance Costs₹76.6 L
Other Expenses₹8 cr
Total Expenses₹75 cr
Profit before Tax₹14 cr
Tax Expense₹2 cr
Net Profit₹12 cr
Net margin on total income13.0%
Where the money goes · H2 FY26
% of total income
Materials + stock-in-trade₹58 cr65.6%
Employee benefit expense₹8 cr8.8%
Finance costs₹76.6 L0.9%
Other expenses₹8 cr9.2%
Tax expense₹2 cr2.5%
Profit for the period₹12 cr13.0%
Total income ₹89 cradds up to ₹100 ✓
Half-yearly results · consolidated (₹ cr)
MetricH1 FY26H2 FY26
Revenue22 cr88 cr
Total income22 cr89 cr
Expenses22 cr75 cr
Profit before tax25.1 L14 cr
Tax6.3 L2 cr
Net profit (owners' share)18.9 L12 cr
Net margin (owners' share, on revenue)0.9%13.1%
EPS (₹)0.136.69
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹146 cr
Shareholder equity
₹107 cr
parent shareholders
Total debt
₹9 cr
Cash
₹19.3 L
Who owns it · 2026-09-30
No pledge
Promoter
72.3%
FII / Foreign
—
DII / Domestic
9.7%
Retail / others
18.0%
Promoter stake up 1.0% over the last 3 quarters.
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 24 Sep 2026
See the official result
1
Adoption of Financial Statements for FY-2025-26
Backed by 100% of shareholders other than promotersneeded 50%
18.50 L votes for, 0 against
2
Re-appointment of the retiring Director
Promoters had a personal stake in this
Backed by 100% of shareholders other than promotersneeded 50%
18.50 L votes for, 0 against
3
Approval for Sale, Transfer and Disposal of Land and Immovable Property
Backed by 100% of shareholders other than promotersneeded 75%
18.50 L votes for, 0 against
4
Approval of Material Related Party Transactions for the financial year 2026-27.
Promoters had a personal stake in this
Backed by 100% of shareholders other than promotersneeded 75%
18.50 L votes for, 0 against

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 25 named members
owning 53.0% between them · as of 2026-09-30
DIVYE CHANDAK10.73%
SUMEET CHANDAK HUF8.25%
SANJAY CHANDAK7.86%
SATYA NARAYAN CHANDAK7.20%
SHEELA CHANDAK5.18%
NEHA CHANDAK5.10%
VITRO BIOTECHNOLOGIES LTD3.81%
JAYSHEE INVESTMENT PVT LTD1.59%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹34 cr raised in Oct 2025 by selling shares to the public

As of Mar 2026, the company says it has spent 92% of what it set aside, leaving ₹3 cr still to be spent. Care Rating watches the spending on the exchange’s behalf.

Funding capital expenditure requirements
73%
₹7 cr of ₹9 cr
Working Capital Requirements
100%
₹16 cr of ₹16 cr
General Corporate Purposes
99%
₹5 cr of ₹5 cr
Issue Related Expenses
95%
₹4 cr of ₹4 cr

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.